Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11993144 | 0.85 | CCR2 (0.41) | KAT6ACCR2SMN1; SMN2LMNAADRB2 | |
| SCHEMBL14200039 | 0.83 | ALDH1A1 (0.40) | KAT6AMAPTTP53ALDH1A1POLB | |
| SCHEMBL11951611 | 0.78 | SLC9A1 (0.50) | ALDH1A1POLBSMN1; SMN2TSHRLMNA | |
| SCHEMBL19574253 | 0.78 | LMNA (0.50) | MAPTALDH1A1POLBSMN1; SMN2TSHR | |
| SCHEMBL16368596 | 0.78 | CNR1 (0.45) | KAT6AMAPTTP53ALDH1A1POLB | |
| SCHEMBL10962414 | 0.77 | RNASEH1 (0.52) | MAPTTP53ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL48556 | 0.76 | NR1H2 (0.34) | MAPTTP53CCR2ALDH1A1CNR1 | |
| SCHEMBL5097716 | 0.75 | CCR2 (0.49) | CCR2SMN1; SMN2PTGS2 | |
| SCHEMBL10407713 | 0.74 | FABP4 (0.46) | ALDH1A1SMN1; SMN2LMNARNASEH1 | |
| SCHEMBL11951547 | 0.74 | L3MBTL1 (0.55) | ALDH1A1SMN1; SMN2LMNARNASEH1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KAT6A 696/4885MAPT 2351/4885TP53 540/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KAT6A 1965/4885MAPT 2574/4885TP53 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.